Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing

Masataka Nakano, Tatsuki Fukami, and Miki Nakajima

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences and WPI Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan

Received May 18, 2019; accepted June 28, 2019

ABSTRACT

Adenosine deaminases acting on RNA (ADARs) enzymes-catalyzing adenosine-to-inosine RNA editing possibly modulates gene expression and function. In this study, we investigated whether ADARs regulate the expression of human constitutive androstane receptor (CAR), which controls the expression of various drug-metabolizing enzymes. CAR mRNA and protein levels in human hepatocellular carcinoma–derived HepG2 cells were increased by knockdown of ADAR1 and slightly increased by ADAR2, indicating that ADARs negatively regulate CAR expression. Increased luciferase activity of a reporter plasmid containing the CYP3A4 promoter region by phenobarbital was augmented by transfection of siRNA for ADAR1 (siADAR1) but not by siADAR2. In addition, the knockdown of ADAR1 resulted in the enhanced induction of CYP2B6 and CYP3A4 mRNA by 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzoyl)oxime and phenobarbital, respectively. These results suggest that ADAR1-mediated downregulation of CAR affects its downstream cytochrome P450 expression.

SIGNIFICANCE STATEMENT

This study revealed that adenosine deaminase acting on RNA 1 (ADAR1) and ADAR2, which catalyze adenosine-to-inosine RNA editing, downregulate the expression of constitutive androstane receptor (CAR) in human liver–derived cells by attenuating splicing. The downregulation of CAR by ADARs affects its downstream cytochrome P450 expression. ADARs would play a role in modulating xenobiotic metabolism potency via regulation of CAR.

Introduction

Understanding the regulatory mechanisms for drug metabolism–related genes is required for the practice of personalized or precision medicine, as well as for promoting efficient drug development. Regulation of gene expression is a multiple-layered process occurring at the levels of transcription, post-transcription, translation, and post-translation. Conventional studies on regulatory mechanisms for drug-metabolizing enzymes have focused primarily on transcriptional regulation. In addition, there is growing evidence showing a great impact of post-transcriptional regulation.

As one of the post-transcriptional regulations, eukaryotic RNA transcripts are subjected to adenosine-to-inosine (A-to-I) RNA editing. A-to-I RNA editing is the most frequent nucleotide conversion type in mammals (Slotkin and Nishikura, 2013; Nishikura, 2016). During the past 10 years, the progress of next-generation sequencing technologies has enabled the high-throughput identification of 4.5 million A-to-I RNA editing sites (Picardi et al., 2017). A-to-I RNA editing is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes. There are two functional members of the ADAR family in humans: ADAR1 and ADAR2. These enzymes have a deaminase domain and double-stranded RNA (dsRNA) binding domains (Kim et al., 1994; Gerber et al., 1997); therefore, they convert adenosines in dsRNA structures into inosines by hydrolytic deamination. Inosine forms base pairs with cytidine as if it was guanosine. Thus, the nucleotide conversion in the coding region possibly changes the amino acid sequence. However, most editing events occur in non-coding regions, such as the introns and untranslated region.
Eagle (Manassas, VA). The cells were cultured in Dulbecco
medium and passed every 3–4 days. Huh7 cells were obtained from the American Type Culture Collection (San Diego, CA). IRDye 680 goat anti-rabbit IgG and goat anti-
human ADAR1 monoclonal antibody (sc-50687) were purchased from Santa Cruz Biotechnology and Toyobo (Osaka, Japan). Mouse anti-human ADAR2 (s1010; siADAR2), and negative control #1 (siControl) were synthesized at IDT Technology (Coraville, IA). Rabbit anti-human GAPDH polyclonal antibody (IMG-5143A) was from IMGENIX (Temecula, CA). Mouse anti-human ADAR1 polyclonal antibody (sc-37454) was purchased from Promega (Madison, WI). RNAiso and random hexamers to synthesize total RNA were purchased from TaKaRa (Kanagawa, Japan). Luna Universal qPCR Master Mix was from New England Biolabs (Ipswich, MA). After incubation for 24 hours, the cells were harvested, and total RNA was prepared.

Evaluation of CYP2B6 and CYP3A4 mRNA Induction. Huh7 cells were seeded and transfected with siRNA as described earlier. After 48 hours, the cells were treated with 100 nM CitoC or 1 mM PB. After incubation for 24 hours, the cells were harvested, and total RNA was prepared.

Real-Time Reverse-Transcription Polymerase Chain Reaction. cDNA was synthesized from total RNA using ReverTra Ace. The used primers are shown in Table 1. A 1-μl portion of the cDNA was added to a polymerase chain reaction (PCR) mixture containing 10 pmol of each primer and 10 μl of the Luna Universal qPCR Master Mix in a final volume of 20 μl. Real-time PCR was performed using Mx3000P (Stratagene, La Jolla, CA) with the MxPro qPCR software.

Materials and Methods

Chemicals and Reagents. Phenobarbital (PB) was purchased from Wako Pure Chemical (Osaka, Japan). 6-4-Chlorophenyl) imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) was purchased from Biomol Research Laboratories (Plymouth Meeting, PA). Lipofectamine RNAiMAX (ThermoFisher Scientific (Waltham, MA). The pGL3-basic vector, pGL3-promoter vector, pGL4.17 vector, pNL1.1 vector, and Nano-Glo Dual-Luciferase Reporter Assay System were obtained from Promega (Madison, WI). RNaiSeq and random hexamers were synthesized at IDT Technology (Corvallis, OR). The AV4-1000 primer, and 0.5 U of GoTaq polymerase (Takara) in a final volume of 25 μl. After an initial denaturation at 94°C for 1 minute, amplification was performed by denaturation at 94°C for 10 seconds followed by annealing/extension at 59°C for 10 seconds for 40 cycles. The PCR conditions for CYP2B6 and CYP3A4 were as follows: after an initial denaturation at 95°C for 10 seconds, amplification was performed by denaturation at 94°C for 10 seconds followed by annealing/extension at 60°C for 20 seconds for 40 cycles. The PCR conditions for CYP3A4 were as follows: after an initial denaturation at 95°C for 10 seconds, amplification was performed by denaturation at 94°C for 10 seconds followed by annealing/extension at 60°C for 20 seconds for 40 cycles. The PCR products were normalized to those of GAPDH (Tsai et al., 2004).

Reverse-Transcription PCR and Direct Sequence Analysis. The sequences of the primers used for the reverse-transcription PCR (RT-PCR) are shown in Table 1. The region, including exon 3, intron 3, and exon 4, was amplified by PCR using cDNA from HepG2 cells. The used primers were CAR ex5 S and CAR ex4 AS, shown in Table 1. The PCR mixture consisted of cDNA, 1× PCR buffer, 10 pmol of each primer, and 0.5 U of Oflox polymerase (Takara) in a final volume of 25 μl. After an initial denaturation at 94°C for 1 minute, amplification was performed by denaturation at 98°C for 10 seconds, annealing at 57°C for 15 seconds, and extension at 72°C for 20 seconds for 32 cycles followed by a final extension at 72°C for 5 minutes. The PCR products were subjected to electrophoresis using a 1.5% agarose gel. The specific products were purified and subjected to direct sequencing.

SDS-PAGE and Western Blot Analysis. For analysis of CAR, ADAR1, and GAPDH protein levels, cell homogenates from HepG2 cells were separated by 10% PAGE, 7.5%, and 10% SDS-PAGE, respectively, and transferred to an Immobilon-P transfer membrane (Millipore, Billerica, MA). To analyze ADAR2 protein levels, the cell homogenates were separated by 10% and 7.5% SDS-PAGE and transferred to a Protran nitrocellulose membrane (Whatman GmbH, Dassel, Germany). The membranes were probed with each primary antibody and the corresponding fluorescent dye–conjugated secondary antibody. The band densities were quantified with an Odyssey Infrared Imaging system (LI-COR Biosciences). The CAR, ADAR1, and ADAR2 protein levels were normalized to GAPDH.

Assessment of the Stability of CAR mRNA. HepG2 cells were transfected with siRNA as described earlier. After 36 hours, the cells were treated with 10 μg/ml α-amanitin, a transcriptional inhibitor. Total RNA was prepared 0, 6, 12, and 24 hours later. The CAR mRNA level was evaluated by real-time RT-PCR as described earlier.
Reporter Plasmid Construction and Luciferase Assay. Reporter constructs containing the promoter region (−2312 to +58 or −317 to +1579) of CAR (Saito et al., 2010), termed pGL4.17/−2312+58 or pGL4.17/−317+1579, were generously provided by Drs. Kosuke Saito and Kaoru Kobayashi (Graduate School of Pharmaceutical Sciences, Chiba University). A reporter plasmid containing the 3′-UTR of CAR was constructed as follows. The 3′-UTR of CAR (+1251 to +1379) was amplified by PCR using HepG2 genomic DNA as a template and inserted into the pGL3p vector at the XbaI site downstream of the luciferase gene. The constructed luciferase reporter plasmid was termed pGL3p/3′-UTR. HepG2 cells were seeded and 5 nM siRNA was transfected as described earlier. After 24 hours, the cells were transfected with

### Table 1

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5′-3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR ex5 S</td>
<td>CAG CTC ATG TCA TCC AT</td>
</tr>
<tr>
<td>CAR ex6 AS</td>
<td>GGC TTC TCG AAC TGT GT</td>
</tr>
<tr>
<td>CAR ex3 S</td>
<td>GTC AAC AAG ACT CAG AGG CG</td>
</tr>
<tr>
<td>CAR ex4 AS</td>
<td>CGT GAT TGA CAA GTT GTC AC</td>
</tr>
<tr>
<td>CAR int3 AS</td>
<td>CCT CTC GAT CTA GAT GTC TA</td>
</tr>
<tr>
<td>CYP2B6 RT S</td>
<td>CTT CGG GAG ATA TGG TGT GA</td>
</tr>
<tr>
<td>CYP2B6 RT AS</td>
<td>TCA AAC AGC TGG CGG AAT AC</td>
</tr>
<tr>
<td>CYP3A4 RT S&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CCA AGC TAT GCT CTT CAG CG</td>
</tr>
<tr>
<td>CYP3A4 RT AS&lt;sup&gt;a&lt;/sup&gt;</td>
<td>TCA GGC TCC ACT TAC GGT GC</td>
</tr>
<tr>
<td>GAPDH RT S&lt;sup&gt;b&lt;/sup&gt;</td>
<td>CCA GGG CTT TTA ACT C</td>
</tr>
<tr>
<td>GAPDH RT AS&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GCT CCC CCC TGC AAA TGA</td>
</tr>
</tbody>
</table>

<sup>a</sup>Takagi et al. (2008).
<sup>b</sup>Tsuchiya et al. (2004).
200 ng of pGL3 or pGL4.17 plasmid and 50 pg of pNL1.1 plasmid. After incubation for 48 hours, luciferase activity was measured with a luminometer using the Nano-Glo Dual-Luciferase Reporter Assay System.

**Evaluation of the Transactivity of CYP3A4 by Luciferase Assay.** A reporter plasmid pCYP3A4-362-7.7K containing the promoter region (−362 to +11) and distal enhancer region (−7836 to −7200) of the CYP3A4 gene was provided by Drs. Kiyoshi Nagata and Yasushi Yamazoe (Graduate School of Pharmaceutical Sciences, Tohoku University). HepG2 cells were seeded into 96-well plates, and 5 nM siRNA was transfected with RNAiMAX. After 24 hours, 200 ng of pCYP3A4-362-7.7K along with 50 pg of pNL1.1 plasmid was transfected. After incubation for 24 hours, these cells were treated with 3 mM PB for 24 hours, and then the luciferase activity was measured. Firefly luciferase activity for each construct was normalized to NanoLuc luciferase activity.

**Statistical Analyses.** Statistical significance was determined by analysis of variance followed by Dunnett’s multiple comparisons test or Tukey’s method test. The comparison of two groups was made with an unpaired, two-tailed Student’s t test. A value of $P < 0.05$ was considered to be statistically significant.

**Results**

Knockdown of ADARs Results in Increases in CAR Expression in HepG2 Cells. To investigate whether ADAR1 and ADAR2 affect human CAR expression, their expressions in HepG2 cells were knocked down using siRNA. As shown in Fig. 1, A and B, ADAR1 and ADAR2 protein levels were significantly decreased by transfection of siADAR1 and siADAR2, respectively. The knockdown of ADAR1 resulted in significant increases in CAR mRNA (Fig. 1C) and protein (Fig. 1D) levels. The knockdown of ADAR2 slightly but significantly increased CAR protein levels (Fig. 1D). These results suggest that ADARs negatively regulate CAR expression.

Knockdown of ADARs Augments the Induction of CYP2B6 and CYP3A4. CAR is activated by some synthetic compounds, drugs, or natural products (Chang and Waxman, 2006) and transactivates target gene expression. We investigated whether the siADAR-mediated upregulation of CAR affects the induction of its downstream CYP3A4 and CYP2B6. First, the effects of knockdown of ADARs on the transactivity of CYP3A4 was evaluated through a luciferase assay using a reporter plasmid containing the CYP3A4 promoter and enhancer regions to which CAR binds (Schuetz et al., 1998; Takada et al., 2004) (pCYP3A4-362-7.7K). Treatment with PB, an activator of CAR, resulted in a significant increase in luciferase activity of pCYP3A4-362-7.7K plasmid in siADAR1-transfected cells but not in siControl- or siADAR2-transfected cells, suggesting that the increase in CAR expression by ADAR1 knockdown enhanced PB-mediated CYP3A4 induction (Fig. 2A).

![Fig. 2. Effects of ADAR1 or ADAR2 knockdown on induction of CYP2B6 and CYP3A4. (A) HepG2 cells were transfected with siADAR1 or siADAR2. After 24 hours, the cells were transfected with pCYP3A4-362-7.7K along with pNL1.1 and siADAR1 or siADAR2. Firefly luciferase activity was normalized to NanoLuc luciferase activity. The values are expressed relative to the pGL3b plasmid. (B and C) After transfection of siADAR1 or siADAR2, the HepG2 cells were treated with 100 nM CITCO (B) or 1 mM PB (C). After 24 hours, CYP2B6 (B) and CYP3A4 (C) mRNA levels were determined by real-time RT-PCR and were normalized to GAPDH. The values are expressed relative to the control. Each column represents the mean ± S.D. of three independent experiments. **$P < 0.01$; ***$P < 0.001$. NT, No treatment.](image-url)
In addition, treatment with CITCO, a ligand of CAR, increased endogenous CYP2B6 mRNA levels in siADAR1-transfected cells but not in siControl- or siADAR2-transfected cells (Fig. 2B). Moreover, CYP3A4 mRNA levels were markedly increased by ADAR1 knockdown, and PB-mediated induction of CYP3A4 mRNA was observed in siADAR1-transfected cells (Fig. 2C). Collectively, these data demonstrated that the upregulation of CAR by knockdown of ADAR1 results in the enhanced induction of its downstream genes.

**Knockdown of ADARs Does Not Affect Transactivity of CAR.** To examine whether the increase in CAR levels by knockdown of ADARs is attributed to the accelerated transcription activation, we performed luciferase assays using the reporter plasmid containing the promoter region of CAR (−2312 to +58 or −317 to +1579). The luciferase activities of pGL4.17/−2312+58 and pGL4.17/−317+1579 were not changed by transfection of siADARs (Fig. 3), indicating that ADARs do not affect the transactivity of CAR.

**Knockdown of ADARs Attenuates Degradation of CAR mRNA.** To examine whether the increase in CAR mRNA by knockdown of ADAR1 is due to the decreased mRNA degradation, the stability of CAR mRNA was evaluated. In the siControl-transfected cells, CAR mRNA level was gradually decreased by treatment with α-amanitin, a transcriptional inhibitor (Fig. 4A). The half-life was calculated to be 6.6 hours. In the siADAR1-transfected cells, CAR mRNA was relatively stable with a half-life of 18.6 hours. These results indicate that the increase in CAR expression by ADAR1 knockdown would be due to the increased stability of CAR mRNA.

To investigate the involvement of the 3’-UTR in ADAR1-mediated regulation of CAR mRNA stability, luciferase assays using a reporter plasmid containing the 3’-UTR of CAR were conducted. The luciferase activity of the pGL3p/3’-UTR plasmid was increased by knockdown of ADARs (Fig. 4B), but similar results were obtained in the case of the pGL3p/empty plasmid. The results suggest that the 3’-UTR is not relevant to the increased stability of CAR mRNA by knockdown of ADAR1.

**Knockdown of ADARs Enhances the Splicing of CAR.** REDIPortal (http://srv00.recas.ba.infn.it/atlas/), a database of RNA-editing sites, indicates that there are 22 RNA-edited sites in intron 3 of CAR. We examined whether ADARs affect the splicing event at intron 3 of CAR. To examine what kinds of transcripts are produced by the splicing of this intron, RT-PCR was performed using CAR ex3S and CAR ex4 AS primers, shown in Fig. 5A. As shown in Fig. 5B, two PCR products were observed in siControl-transfected cells. Direct sequence analysis revealed that the longer (2746 bp) and shorter (233 bp) products corresponded to the unspliced and spliced transcripts, respectively. By the analysis of the sequence of the unspliced transcript, we noticed that there are no RNA-edited sites in the intron 3 of CAR, because overlapped peaks of “G” to “A” were not observed, as shown in a typical sequencing electropherogram (Fig. 5C), even though this region includes RNA-edited sites registered in REDIPortal (shown by vertical arrows). The band intensities of the unspliced and spliced transcripts were decreased and increased by knockdown of ADAR1, respectively. Since RT-PCR lacks quantitativeness, real-time RT-PCR analyses, in which unspliced transcript and spliced transcript would be specifically amplified, were performed for quantitative evaluation. CAR ex3 and CAR int 3 AS primers were used to evaluate the unspliced transcript. CAR ex3 and CAR ex4 AS primers were used to amplify only the spliced transcript, and the extension time was set to be shorter than that in RT-PCR, as described in detail in the Materials and Methods section. As shown in Fig. 5D, the level of the unspliced CAR transcript tended to be decreased by knockdown of ADARs, whereas that of the spliced CAR transcript was significantly increased by knockdown of ADARs. These results indicated that ADARs attenuate the splicing of CAR intron 3 in an RNA editing–independent manner, possibly resulting in downregulation of CAR expression.

**Discussion**

The expression of CAR is regulated at the transcriptional level by transcription factors, such as glucocorticoid receptor (Pascussi et al., 2003), hepatocyte nuclear factor 4α (Wieneke et al., 2007), and retinoic acid receptor (Saito et al., 2010). The present study demonstrated a new post-transcriptional regulatory mechanism:
ADAR1 negatively regulates the expression of CAR by attenuating splicing.

Splicing is a process to remove introns from pre-mRNA and ligate adjacent exons to form mature mRNA. Most introns are flanked by 5′-GT-AG-3′ splice sites, and RNA editing in introns has the potential to affect splicing (Samuel, 2019). The first example of RNA editing–dependent alternative splicing during the processing of pre-mRNA was ADAR2-mediated autoediting of its own pre-mRNA. This autoediting creates a 3′AG splice site (AA changed to AI), leading to alternative splicing (Dawson et al., 2004). Recently, it was reported that intronic editing of the heterogeneous nuclear ribonucleoprotein L-like transcript by ADAR1 and ADAR2 generates another variant containing an additional exon (Chen et al., 2018). We noticed that 22 RNA-edited sites are registered within the two inverted Alu elements, which can form dsRNA structures, in intron 3 of CAR in REDIportal. We found that the knockdown of ADARs enhances the efficiency of splicing at intron 3 (Fig. 5). We examined whether intron 3 of CAR pre-mRNA in HepG2 cells was actually subjected to RNA editing by direct sequence analysis using the longer PCR product (2746 bp) in Fig. 5B. As a result, no editing sites were observed in the two Alu elements located in intron 3 of CAR (the typical result is shown in Fig. 5C). Recently, growing evidence suggests that ADARs have potential to regulate gene expression in an RNA editing–independent manner. A study reported that overexpression of active (wild-type) or inactive (by an amino acid change, E397A) ADAR2 causes aberrant splicing of its own pre-mRNA, suggesting an RNA editing–independent role of ADAR2 in splicing (Agranat et al., 2010). In addition, ADAR1 competitively inhibits binding of staufen1 to the dsRNA in the 3′-UTR of cyclin G1 or cancer susceptibility candidate 5 to antagonize Staufen1-mediated mRNA decay in an RNA editing–independent manner (Sakurai et al., 2017). The editing-independent function would require only dsRNA binding domains but not the deaminase domain of ADAR proteins. Referring to these examples, it can be assumed that ADAR1 may bind to the dsRNA structure in intron 3 of CAR pre-mRNA, leading to the inhibition of splicing.

Aberrant splicing products are degraded by nonsense-mediated mRNA decay, a mechanism that eliminates mRNAs containing premature translation-termination codons (PTCs) (McGlincy and Smith, 2008). We found that knockdown of ADAR1 attenuated the degradation of CAR mRNA through enhancing the efficiency of splicing (Fig. 4A). We noticed that the retention of intron 3 in CAR mRNA results in the creation of PTCs (data not shown). Collectively, ADAR1 causes aberrant splicing of CAR pre-mRNA to create PTC, possibly leading to the degradation of the aberrant transcript by nonsense-mediated mRNA decay.

Recently, we reported that ADARs regulate the P450 isoform in HepaRG cells (Nozaki et al., 2019). In that study, an increase in CYP3A4 expression by knockdown of ADAR1 was observed. CYP3A4 is a target gene (Schuetz et al., 1998; Takada et al., 2004) of CAR. The present study demonstrated that the knockdown of ADAR1 resulted in enhanced PB-mediated transactivation of CYP3A4 (Fig. 2A) and increased levels of endogenous CYP3A4 mRNA (Fig. 2C). Therefore, the upregulation of CAR by knockdown of ADAR1 would be one of the underlying mechanisms of the increased CYP3A4 expression by knockdown of ADAR1. In addition to CYP3A4, CYP2B6 transcription is also regulated by CAR (Hedrich et al., 2016). There are large interindividual differences in CYP3A4 (50-fold) and CYP2B6 (158-fold) expressions in human livers (Ozdemir et al., 2000; Rodriguez-Antona et al., 2001). Our previous study revealed a large interindividual variation (220-fold) in hepatic ADAR1 protein levels (Nakano et al., 2016). Therefore, it is possible that the variation in ADAR1 expression could be one of the factors causing the interindividual variation in such CAR-regulated P450 expression. It remains unknown what factors cause the interindividual difference in hepatic ADAR1 expression. It is worth investigating whether xenobiotics such as drugs, herbal products, and environmental pollutants or genetic polymorphisms affect ADAR expression or function. Such knowledge would enhance the significance of ADAR-mediated post-transcriptional regulation in drug metabolism.

CAR regulates not only drug-metabolizing enzymes but also energy metabolism. It has been reported that activation of CAR leads to amelioration of some metabolic diseases, such as
atherosclerosis (Sberna et al., 2011), obesity (Gao et al., 2009), fatty liver disease (Dong et al., 2009), and diabetes (Dong et al., 2009). In addition, CAR is involved in the exacerbation of hepatic fibrosis in a mouse dietary model of nonalcoholic steatohepatitis (Yamazaki et al., 2007). A recent study reported that hepatocyte-specific ADAR1 knockout mice display massive liver damage with fibrogenesis, suggesting that ADAR1 restrains the development of hepatic fibrosis (Ben-Shoshan et al., 2017). Combined with the present findings that ADAR1 negatively regulates CAR expression, a possibility is surmised that ADAR1 has a role in protecting the liver from fibrosis by repressing CAR expression. It is worth investigating such a possibility in future studies. It is of interest to examine whether the interindividual difference in ADAR1 expression may cause interindividual variability in the CAR-regulating hepatic function.

In conclusion, we found that ADAR1 downregulates CAR expression by repressing splicing of CAR and facilitating its mRNA degradation. ADAR1 may have a role in control of liver function, including drug metabolism and energy metabolism, via regulation of CAR. The present study provided new insights into ADAR-mediated gene regulation and the potential biologic significance of hepatic ADAR1.

Acknowledgments

The authors thank Dr. Kiyoshi Nagata and Dr. Yasushi Yamazoe (Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan) for providing pCYP3A4-362-7.7K plasmid and Dr. Kosuke Saito and Dr. Kaoru Kobayashi (School of Pharmaceutical Sciences, Chiba University) for providing pGL4.17/-2312 and pGL4.17/-317/1579.

Authorship Contributions

Participated in research design: Nakano, Fukami, Nakajima.
Conducted experiments: Nakano.
Contributed new reagents or analytic tools: Nakano.
Performed data analysis: Nakano, Nakajima.
Wrote or contributed to the writing of the manuscript: Nakano, Nakajima.
Regulation of Human CAR Expression by ADARs

References


Address correspondence to: Dr. Miki Nakajima, Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University Kakuma-machi, Kanazawa 292-1192, Japan. E-mail: mnikke@kkanazawa-u.ac.jp

Downloaded from jpet.aspetjournals.org at ASPF Journals on October 6, 2022